Excision of HIV-1 Proviral DNA by Recombinant Cell Permeable Tre-Recombinase
暂无分享,去创建一个
J. Hauber | F. Buchholz | E. Hildt | A. Grundhoff | H. Hofmann-Sieber | Lakshmikanth Mariyanna | Poornima Priyadarshini | Marcel Krepstakies | N. Walz
[1] F. Edenhofer,et al. Genetic engineering of mammalian cells by direct delivery of FLP recombinase protein. , 2011, Methods.
[2] C. Elmets,et al. Prospects for skin cancer treatment and prevention: the potential contribution of an engineered virus. , 2011, The Journal of investigative dermatology.
[3] J. Hauber,et al. Gene Therapy Strategies: Can We Eradicate HIV? , 2011, Current HIV/AIDS reports.
[4] J. Rossi,et al. An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4+ T Cell Decline in Humanized Mice , 2011, Science Translational Medicine.
[5] J. Hauber,et al. In vitro evolution and analysis of HIV-1 LTR-specific recombinases. , 2011, Methods.
[6] B. Berkhout,et al. Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. , 2011, Antiviral research.
[7] A. Rein,et al. RNA Aptamers Directed to Human Immunodeficiency Virus Type 1 Gag Polyprotein Bind to the Matrix and Nucleocapsid Domains and Inhibit Virus Production , 2010, Journal of Virology.
[8] J. McCune,et al. Can HIV be cured with stem cell therapy? , 2010, Nature Biotechnology.
[9] Vanessa Taupin,et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.
[10] Anitha Rao,et al. RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.
[11] K. Breckpot,et al. Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential , 2010, Archivum Immunologiae et Therapiae Experimentalis.
[12] Amalio Telenti,et al. Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .
[13] Marie-Pierre de Béthune,et al. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.
[14] T. Cihlar,et al. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. , 2010, Antiviral research.
[15] M. de Béthune. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.
[16] R. Doms,et al. Entry inhibitors in the treatment of HIV-1 infection. , 2010, Antiviral research.
[17] A. Wensing,et al. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. , 2010, Antiviral research.
[18] Xiaowu Chen,et al. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. , 2010, Antiviral research.
[19] E. De Clercq,et al. Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides. , 2010, Antiviral research.
[20] S. Broder,et al. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. , 2010, Antiviral research.
[21] Shana O Kelley,et al. Recent advances in the use of cell-penetrating peptides for medical and biological applications. , 2009, Advanced drug delivery reviews.
[22] Frank Buchholz,et al. Dre recombinase, like Cre, is a highly efficient site-specific recombinase in E. coli, mammalian cells and mice , 2009, Disease Models & Mechanisms.
[23] M. Morris,et al. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics , 2009, British journal of pharmacology.
[24] B. Hirschel,et al. A new era of antiretroviral drug toxicity , 2008, Antiviral therapy.
[25] M. Rapoport,et al. TAT-based drug delivery system--new directions in protein delivery for new hopes? , 2009, Expert opinion on drug delivery.
[26] B. Berkhout,et al. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2-/-γc-/-) mouse model , 2009, Gene Therapy.
[27] J. Orange,et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.
[28] M. Morris,et al. Cell‐penetrating peptides: from molecular mechanisms to therapeutics , 2008, Biology of the cell.
[29] M. Morris,et al. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. , 2008, Advanced drug delivery reviews.
[30] Vladimir P Torchilin,et al. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. , 2008, Biopolymers.
[31] John J Rossi,et al. Genetic therapies against HIV , 2007, Nature Biotechnology.
[32] R. Jäger,et al. Enhanced purification of cell‐permeant Cre and germline transmission after transduction into mouse embryonic stem cells , 2007, Genesis.
[33] J. Hauber,et al. HIV-1 Proviral DNA Excision Using an Evolved Recombinase , 2007, Science.
[34] Z. Popović,et al. Effect of Cell-Based Intercellular Delivery of Transcription Factor GATA4 on Ischemic Cardiomyopathy , 2007, Circulation research.
[35] David J. Mooney,et al. Microenvironmental regulation of biomacromolecular therapies , 2007, Nature Reviews Drug Discovery.
[36] A. Schambach,et al. Retrovirus vectors: toward the plentivirus? , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[37] A. Nienhuis,et al. Genotoxicity of retroviral integration in hematopoietic cells. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[38] H. Will,et al. Identification of a structural motif crucial for infectivity of hepatitis B viruses. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[39] P. Hofschneider,et al. A novel system for efficient gene transfer into primary human hepatocytes via cell‐permeable hepatitis B virus–like particle , 2005, Hepatology.
[40] E. Hildt,et al. Protein transduction with bacterial cytosine deaminase fused to the TLM intercellular transport motif induces profound chemosensitivity to 5-fluorocytosine in human hepatoma cells. , 2005, Journal of hepatology.
[41] H. Ruley,et al. Enhanced cell-permeant Cre protein for site-specific recombination in cultured cells , 2004, BMC biotechnology.
[42] David A. Williams,et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[43] E. Hildt,et al. Reconstitution of gene expression from a regulatory‐protein‐deficient hepatitis B virus genome by cell‐permeable HBx protein , 2003, EMBO reports.
[44] J. Montaner,et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.
[45] Mark A. Kay,et al. Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.
[46] S. Dowdy,et al. Modulation of cellular function by TAT mediated transduction of full length proteins. , 2003, Current protein & peptide science.
[47] Eric Vives,et al. Cell-penetrating Peptides , 2003, The Journal of Biological Chemistry.
[48] M. Lindsay. Peptide-mediated cell delivery: application in protein target validation. , 2002, Current opinion in pharmacology.
[49] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.
[50] A. Gewirtz,et al. Nucleic-acid therapeutics: basic principles and recent applications , 2002, Nature Reviews Drug Discovery.
[51] F. Sharp,et al. In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis , 2002, The Journal of Neuroscience.
[52] C. Stocking,et al. Unmodified Cre recombinase crosses the membrane. , 2002, Nucleic acids research.
[53] M. Eder,et al. Gene transfer into hematopoietic stem cells using lentiviral vectors. , 2002, Current gene therapy.
[54] M. Morris,et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells , 2001, Nature Biotechnology.
[55] Douglas D. Richman,et al. HIV chemotherapy : AIDS , 2001 .
[56] Douglas D. Richman,et al. HIV chemotherapy , 2001, Nature.
[57] E. Hildt,et al. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens , 2000, Gene Therapy.
[58] W. Fawzi,et al. Transmission of human immunodeficiency type 1 viruses with intersubtype recombinant long terminal repeat sequences. , 1999, Virology.
[59] Natalie A. Lissy,et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.
[60] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[61] E A Emini,et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.
[62] G. Elliott,et al. Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein , 1997, Cell.
[63] A. Prochiantz,et al. The third helix of the Antennapedia homeodomain translocates through biological membranes. , 1994, The Journal of biological chemistry.
[64] J Barsoum,et al. Tat-mediated delivery of heterologous proteins into cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[65] H. Field,et al. Antiviral drug resistance. , 1989, Trends in pharmacological sciences.
[66] William D. Richardson,et al. A short amino acid sequence able to specify nuclear location , 1984, Cell.